Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VericelVCEL +1.38%83 Cash-to-Debt is 1.76 as of Jun. 2026, which is at its 10-year median of 1.76. GuruFocus rates VCEL with a GF Score™ of 83/100 and a GF Value™ of $53.98 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 1,343 Biotechnology companies, Vericel ranks worse than 70.14% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Vericel's cash to debt ratio for the quarter that ended in Jun. 2026 was 1.76.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Vericelcould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Vericel's Cash-to-Debt or its related term are showing as below:
VCEL'
s Cash-to-Debt Range Over the Past 10 Years
Min: 1.04 Med: 1.76 Max: No Debt
Current: 1.76
During the past 13 years, Vericel's highest Cash to Debt Ratio was No Debt. The lowest was 1.04. And the median was 1.76.
VCEL's Cash-to-Debt is ranked worse than 70.14% of 1343
companies
in the Biotechnology industry
Industry Median: 7.25
vs VCEL: 1.76
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Vericel Cash-to-Debt Related Terms
Vericel Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Vericel's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, Vericel's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vericel Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vericel's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Vericel's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vericel (VCEL) has a Cash-to-Debt of 1.76 as of Jun. 2026. This is near median its historical median of 1.76. Over the past decade, Vericel's Cash-to-Debt has ranged from 1.04 to 10,000.00. According to the industry distribution chart, Vericel ranks #942 out of 1343 companies in the Biotechnology industry, placing it in the top 70.1%.
Is Vericel's Cash-to-Debt too high?
Vericel's current Cash-to-Debt of 1.76 is near median its 10-year median of 1.76. Over the past 10 years, this metric has ranged from a low of 1.04 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 7.25. Vericel's value of 1.76 is 75.7% below this industry median. Based on the distribution chart, Vericel ranks #942 out of 1343 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Vericel has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vericel's Cash-to-Debt compare to KLRA and MLYS?
According to the Biotechnology industry distribution chart, Vericel ranks #942 out of 1343 companies for Cash-to-Debt. This places Vericel in the lower half of its industry. The industry median Cash-to-Debt is 7.25. Vericel's value of 1.76 is 75.7% below this benchmark. Historically, Vericel's own Cash-to-Debt has ranged from 1.04 to 10,000.00 over the past decade. While the company's 10-year median is 1.76 vs. the industry median of 7.25, Vericel has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 7.25, based on 1,343 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vericel's current Cash-to-Debt of 1.76 is 75.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 7.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vericel's current Cash-to-Debt is 1.76, which is near median its own 10-year median of 1.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vericel stock overvalued right now?
Based on GuruFocus' analysis, Vericel (VCEL) is currently considered Modestly Undervalued. The stock's GF Value™ is $53.98, compared to a current price of $42.65 — trading 21% below its estimated fair value. The current Cash-to-Debt is 1.76, which is near median its 10-year median of 1.76 and 75.7% below the Biotechnology industry median of 7.25. Vericel's overall GF Score™ is 83/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Vericel (VCEL), the current Cash-to-Debt is 1.76 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vericel (VCEL) Overvalued in 2026?
Based on GuruFocus' analysis, Vericel stock appears to be undervalued.
The current stock price of $42.65 is trading 21% below its estimated GF Value™ of $53.98.
GuruFocus considers Vericel to be Modestly Undervalued.
Key valuation signals for VCEL:
Cash-to-Debt: 1.76 (near median its 10-year median of 1.76)
GF Value™: $53.98 vs. price of $42.65 (21% below fair value)
Industry Position: 75.7% below the Biotechnology median (#942 of 1343)
No single metric tells the full story. See the VCEL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
83GF Score
Get the complete analysis for VCEL
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VCEL has been successfully added to your 
